Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients

Clinical Therapeutics

Volumn 20, Issue 3, 1998, Pages 567-580

  Balkrishnan, Rajesh ^a   Norwood, G Joseph ^a   Anderson, Andrea ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Cost benefit; Inhaled corticosteroids; Medicaid; Outcomes

Indexed keywords

CORTICOSTEROID;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COST BENEFIT ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; TREATMENT OUTCOME;

EID: 0031902619     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80066-0     Document Type: Article

References (22)

1. Pearce N, Beasley R, Burgess C, et al. Asthma Epidemiology, Principles and Methods. New York: Oxford University Press; 1998;75-79.
2. Mellis CM, Peat JK, Woolcock AJ. The cost of asthma: Can it be reduced? PharmacoEconomics. 1993;3:205-219.
3. Bauman A, Mitchell CA, Henry RL, et al. Asthma morbidity in Australia: An epidemiological study. Med J Aust. 1992;156: 827-831.
4. Col N, Fanale J, Kronholm P. The role of medication non-compliance and adverse drug reactions in the hospitalizations of the elderly. Arch Intern Med. 1990;150: 841-845.
5. Fong PM, Sinclair DE. Inhalation devices for asthma. Can Fam Phys. 1993;39: 2377-2382.
6. Expert Panel Report II: Guidelines for Diagnosis and Management of Asthma. Bethesda, Md: National Heart, Lung, and Blood Institute, 1997.
7. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. NEJM. 1992;326:862-866.
8. Pharmaceutical Benefits Under the State Medical Assistance Programs. Reston, Va: National Pharmaceutical Council, 1995: 79-226, 428-431.
9. Wissow LS, Gittelsohn AM, Szko M, et al. Poverty, race and hospitalization for childhood asthma. Am J Public Health. 1988;78:777-782.
10. Carr W, Zeitel L, Weiss KB. Variations in asthma hospitalizations and deaths in New York City. Am J Public Health. 1992;82: 59-65.
11. Nightingale CH. Cost comparison of beta 2-agonist bronchodilators used in the treatment of asthma. Pharmacotherapy. 1995; 15:677-681.
12. Sculpher MJ, Buxton MJ. Episode free day as a composite measure of cost effectiveness. PharmacoEconomics. 1993;4: 345-352.
13. Tierce JC, Meller W, Berlow B, et al. Assessing the cost of albuterol inhalers in the Michigan and California Medicaid programs. Clin Ther. 1989;11:53-61.
14. Rutten-Van Molken MPMH, Doorslaer EKAV, Jansen MCC, et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151:975-982.
15. Rutten-Van Molken MPMH, Doorslaer EKAV, Jansen MCC, et al. Cost effectiveness of inhaled corticosteroid plus bronchodilator versus bronchodilator monotherapy in children with asthma. PharmacoEconomics. 1993;4:257-270.
16. Perera BJC. Efficacy and costs of inhaled steroids in asthma in a developing country. Arch Dix Child. 1995;72:312-316.
17. Eisenberg JM. Clinical economics: A guide to the economic analysis of clinical practices. JAMA. 1989;262:2879-2885.
18. International Classification of Diseases, 9th Revision. Los Angeles, Calif: PMIC; 1995.
19. 1996 Drug Topics® Red Book. Montvale, NJ: Medical Economics: 1996.
20. American Medical Association. CPT 1995: Physicians' Current Procedural Terminology. Salt Lake City, Utah: Medicode Inc.; 1995.
21. Suissa S, Biais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal and near fatal asthma. Eur Respir J. 1994;7:1602-1609.
22. Bureau of Labor Statistics. Available at: Consumer Price Index summary. http://stats.bls.gov. Accessed July 15, 1997.